Introduction
Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) playing a key role in innate immune defense against a wide diversity of pathogens [1, 2] . TLRmediated recognition of highly conserved so-called 'pathogen-associated molecular patterns (PAMPs)' initiates complex signaling cascades, culminating in the activation of transcription factors such as nuclear factor (NF)kB and interferon regulatory factor (IRF)-7 [3, 4] . The resulting differential gene expression, which varies depending on which TLR has been activated, leads to potent innate immune responses against the pathogen and modifies the adaptive immune response.
Ten human TLRs have been identified [5] . Although TLR research initially concentrated on bacterial PAMPs, it is now firmly established that viruses also interact with the TLR system [6] . TLRs implicated in the response to viral stimulation include TLR7 and TLR8 sensing viral single-strand RNA [7] [8] [9] . The outcome of viral TLR activation exhibits wide individual variation ranging from effective antiviral response to viral replication and spread [10] .
Individual variation of the host response is particularly important for HIV. HIV-1 RNA activates TLR7/8 [8, 11, 12] . For both, TLR7 stimulation and TLR8 stimulation, an anti-HIV effect has been demonstrated depending on an enhancement of the adaptive [13, 14] , and also the innate immune response [15, 16] . In acute HIV-infection, TLR8-induced HIV-restriction depends on unknown soluble factors [15] , whereas TLR7-induced HIVconstraint is governed mainly by IFNa [16] . HIV-1 RNA induces the release of IFNa in plasmacytoid dendritic cells (pDCs) via TLR7 activation [11] ; type I interferons induce a wide range of antiretroviral factors and potently restrict HIV-1 replication in vitro [17] [18] [19] [20] [21] [22] [23] and in vivo [24] [25] [26] .
Conversely, TLR ligands have been demonstrated to mediate a continuous activation of the immune system driving viral replication and progression to AIDS [27] [28] [29] . As the HIV-long terminal repeat (LTR) contains NFkB transcription sites, TLR-triggered NFkB activation leading to LTR-dependent transcription is viewed as one of the mechanisms for increased HIV-1 replication [15, 27, [29] [30] [31] . Furthermore, immune activation has been implicated with natural killer (NK)-cell activation in viremic HIV infection and is regarded as a hallmark of chronic HIV-1 disease [32] . Recent evidence suggests that HIV itself contributes substantially to this process by TLR7/8 ligation of viral RNA [12, 33, 34] . The progression of HIV disease might therefore depend on the complex balance of TLR7/8-mediated-immune activation, a mechanism favorable to the virus, and TLR7/8-mediated induction of IFNa and other soluble factors, a mechanism favorable to the host. TLR7 employs the adaptor molecule MyD88 for the induction of both IFNa and inflammatory responses. Downstream, the signaling pathway splits: IFNa is induced through the activation of IRF7, whereas inflammatory cytokines such as IL-6 are induced through activation of NF-kB. The IRF7/IFN and the NF-kB/IL6 pathway have common as well as distinctive signaling mediators [35] [36] [37] [38] . In certain experimental settings, it has been shown that the signaling threshold of the TLR axis is higher for IFNa induction than for NF-kB-dependent interleukin induction [39] .
The importance of TLR7/8-mediated innate immune responses for HIV-1 disease outcome has become increasingly evident during the last years. The use of TLR7/ 8-specific agonists and antagonists is discussed as a novel approach for HIV-1 treatment [15, 32, 33] . Genetic variants of TLRs and downstream signaling molecules can influence the ability of the affected individual to respond to TLR ligands resulting in an altered susceptibility to or course of infectious disease [40] [41] [42] . Regarding HIV, it is established that variations within the host's genome contribute to the risk for acquiring infection as well as the individual rate of disease progression [43] [44] [45] [46] [47] [48] .
However, data on the relation between HIV-1 infections and TLR 7/8 single nucleotide polymorphisms (SNPs) are scarce and there is currently a lack of studies on the functional effects of TLR7/8 genetic polymorphisms [49] . We were recently able to show that a common TLR8 mutation restricts HIV-1 disease progression, possibly by decreasing NFkB activation [50] , and that the course of another RNA viral disease, hepatitis C virus (HCV) infection, correlates with the presence of certain TLR7 genotypes [51] . We hypothesized that genetic variations of TLR7 might be functionally relevant and influence the progression of HIV disease. Here we show that a common TLR7 genetic variant restricting IFNa but not inflammatory responses is associated with higher viral loads as well as accelerated disease progression in HIV-1-infected individuals. This is the first functional study of a TLR7 genetic variant affecting the progression of HIV-1 disease.
Material and methods

Sample genotyping
Three coding nonsynonymous TLR7 SNPs were determined in the study group by real-time PCR assays. Of these, two (Gln11Leu, Ala448Val) are coding nonsynonymous SNPs reported at an allelic frequency of more than 1% in the Entrez dB SNP database (http://www. ncbi.nlm.nih.gov/sites/entrez?db=snp and http://www. ensembl.org/); the third (T-120G) was previously identified to be related to another RNA-viral disease, HCV infection [51] . Whereas Gln11Leu and Ala448Val are located to exon 3 of the TLR7 gene, T-120G is an intronic polymorphism. The detailed PCR curve and melting curve analysis methodology is available online in the Supplementary Methods section.
Study population
The study group comprised a total of 1279 individuals of either White or African ethnicity, 734 HIV-1-positive adults [men 671 (91%); women 63 (9%); Whites 708 (96.5%); Africans 26 (3.5%); median age, 39 years (interquartile range, IQR, 34-43 years)], and 545 seronegative controls [men 489 (90%); women 56 (10%); Whites 510 (94%); Africans 35 (6%); median age 38 years (IQR 30-43 years)].
Seropositive individuals are HIV-1 patients either enrolled in the German HIV-1 Seroconverter Study (n ¼ 646) or in the Berlin Trial on HIV and TLR SNPs (n ¼ 88). The German HIV-1 Seroconverter Study is a nationwide study based on a cohort of HIV-infected individuals for whom the date of seroconversion can be reliably estimated as the midpoint between the last negative and the first positive HIV-1 antibody test within a maximum interval of 3 years, or the date of the first reactive test if acute seroconversion was documented [52] [53] [54] . The Berlin Trial on HIV and TLR SNPs was established for the purpose of this study and enrolled seroconverters (n ¼ 24) and seroprevalent patients (n ¼ 64) for whom the date of seroconversion has not been documented. Further details on both study cohorts are provided online in the Supplementary Methods section. For disease progression analyses, set point viral loads (available for 302 HIV-1 infected individuals; see Statistical Methods for definition) and, in Kaplan-Meier analysis of 464 seroconverters, the time from seroconversion to advanced immunosuppression as defined by a CD4 þ T-cell count less than 350 ml were assessed. To preclude confounding effects, CD4 þ T-cell count and viral load values gathered before the start of any antiretroviral treatment were considered only. Furthermore, carriers of the established HIV-protective CCR5D32 deletion [43, [55] [56] [57] [58] [59] [60] were excluded in a second step of both viral load and survival analysis.
The HIV-negative control collective consisted of 425 anonymized seronegative White blood donors and 120 healthy, unrelated volunteers. This group has been previously described [50] ; for the survey reported here, 53 individuals (48 cases, five controls) were excluded from analysis, either because TLR7 genotyping was not feasible or because they were of rare or unknown ethnicity. Informed consent has been obtained, and written approval from the relevant ethical boards has been granted for all studied participants.
Statistical methods
Genotype frequencies of seropositive and seronegative individuals were compared using x 2 tests. Viral set points, defined as the median of all values of log 10 -transformed copies of HIV-1 RNA measured in plasma between 100 days and 2 years postseroconversion [47, 61] , were available for 302 therapy-naive patients. To evaluate the correlation between TLR7 genotypes and viral load, individual set points in each genetic group were compared by the nonparametric Mann-Whitney test. Survival analysis was conducted using the Kaplan-Meier method with an endpoint of less than 350 CD4 þ T cells/ml. Differences between genotypes were analyzed by the log-rank test. P values less than 0.05 were considered statistically significant. We used SPSS14.01 software (SPSS Inc., Chicago, Illinois, USA) for data management and statistical analyses, and PRISM 4 for figures.
Isolation and stimulation of peripheral blood mononuclear cells Whole blood was obtained from age-matched pairs of healthy volunteers differing in their TLR7Gln11Leu genotype. All donors were healthy White males negative for the TLR7 T-120G, TLR7 Ala448Val and TIRAP Ser180Leu polymorphisms who had given written informed consent before donation. Detailed protocols for isolation and cultivation of peripheral blood mononuclear cells (PBMCs) are provided online in the Supplementary Methods section.
After seeding, cells were stimulated with 100 ml supplemented medium per well containing the respective ligands Imiquimod (Invivogen, Toulouse, France) and lipopolysaccharide (LPS) (Re595; Sigma, Deisenhofen, Germany) at the indicated concentrations. IFNa and IL-6 protein levels were measured from cell culture supernatants in a sandwich enzyme-linked immunosorbent assay (ELISA) procedure, which is supplied in detail in the Supplementary Methods section.
Results
To test the hypothesis that TLR7 genetic variation is related to the risk for, or the course of HIV-1 infection, distribution of three polymorphisms was analyzed in a total study population of 1279 participants. Of these, 734 were HIV-1 positive individuals and 545 were seronegative controls, matched according to age, ethnicity and sex.
Distribution of toll-like receptor 7 mutant alleles in HIV-1 patients and controls
If presence of a certain gene variant modifies the susceptibility to HIV-1, its frequency should vary between seropositive and seronegative populations. Thus, we compared TLR7 polymorphism frequencies for HIV-1-infected patients and controls. Because of the X-chromosomal localization of the TLR7 gene, analyses were conducted separately according to sex ( Table 1) .
The TLR7 T-120G polymorphism was found in White participants only and was absent in Africans. In White males, the proportion of hemizygotes ranged between 4.9% in seronegatives and 5.8% in seropositives; this difference was not significant. In women, the frequency of heterozygotes among HIV patients (12.7%) was similar as observed for healthy controls (10.7%).
The TLR7 Ala448Val alteration was found to be rare, with a total of eight SNP carriers detected in the entire study collective. All of these were White males. Two of them were HIV-infected, whereas the other six hemizygotes belonged to the seronegative control group corresponding to proportions of 0.3 and 1.3%, respectively.
Regardless of serostatus, ethnicity, and sex TLR7
Gln11Leu represented the single most common genetic variation in all subgroups examined. In men, frequencies of hemizygotes were roughly similar in HIV-patients (23.4%) and in HIV-negative controls (20.9%; P ¼ 0.305). By contrast, in HIV-infected women the mutant allele carriage frequency was significantly higher than that observed in healthy controls (P ¼ 0.002). This distinction remained significant when analysis was restricted to women of either White or African ethnic background. The association might represent a stochastic event, given the low number of women in our study collective. However, it may also indicate that female carriers of the TLR7 Gln11Leu variant allele are at an increased risk of being infected with HIV-1.
Association of toll-like receptor 7 polymorphisms with HIV-1 disease progression
We next examined whether either of the two common TLR7 SNPs examined here, TLR7 T-120G and TLR7 Gln11Leu, were related to the severity of HIV-1 disease. To this end, we first analyzed baseline CD4 þ T-cell counts and observed lower CD4 þ T-cell counts in male TLR7 Gln11Leu mutation carriers as compared with carriers of the common allele ( Supplementary Table S1 ). To assess 300 AIDS 2009, Vol 23 No 3 the influence of these polymorphisms on disease progression, we examined their association with set point viral loads and with the endpoint of less than 350 CD4 þ T cells/ml, which signifies immunologically advanced HIV-1 infection. Because of the low number of women with these parameters available, analysis was confined to male seropositives.
Impact of toll-like receptor 7 genotype on HIV-1 set point viral load
We observed no association between TLR7 T-120G genotype and set point plasma viral loads (see Material and Methods for a definition), implying that this polymorphism does not play a role in establishing steady-state levels of HIV-1 after seroconversion (Table 1) .
Regarding TLR7 Gln11Leu genotype, however, males hemizygous for the rare 'Leu' alteration displayed significantly higher set point viral loads implying a deleterious effect of the minor gene variant (P ¼ 0.017; Fig. 1a ). To exclude confounding issues resulting from different ethnic backgrounds, the analysis was limited to Whites and this difference remained significant (P ¼ 0.013; data not shown). When individuals heterozygous for the HIV-1 protective CCR5D32 deletion were excluded from analysis, the distinction between genotypes was more pronounced (P ¼ 0.006; Fig. 1b ).
Relation between toll-like receptor 7 genotype and advanced immunological stage of HIV-1 infection A CD4 þ T-cell count less than 350/ml is the immunological criterion for advanced HIV-1 disease in adults; it firmly indicates the need to initiate antiretroviral therapy according to the revised European [62] and American [63] guidelines. We hypothesize that the time until the CD4 þ T-cell number reaches 350/ml depends on TLR7 genetic variation.
Although no such association was observed for the TLR7 T-120G SNP (data not shown), Kaplan-Meier analysis of 464 seroconverters revealed that TLR7 Gln11Leu hemizygotes took a median time of 17 [95% confidence interval (CI): [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] months to reach the study endpoint of less than 350 CD4 þ T cells/ml, whereas carriers of the normal gene variant took a median 32 [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] months, indicating an accelerated disease course in Gln11Leu mutation carriers. This difference was significant (P ¼ 0.021; Fig. 2a ), remained so when only Whites were considered (P ¼ 0.020; data not shown), and was more pronounced in the subgroup of individuals negative for the CCR5D32 deletion (P ¼ 0.011; Fig. 2b ).
We conclude that presence of the TLR7 Gln11Leu genetic variation is associated with a detrimental effect on HIV-1 disease progression as defined by viral set points and the time in reaching a stage of immunologically advanced infection. This prompted us to study the functional impact of the Gln11Leu polymorphism by use of ex-vivo cell stimulation assays.
Effect of the Gln11Leu polymorphism on toll-like receptor 7 stimulation ex vivo
This SNP is common in White populations providing a chance to examine its functional relevance ex vivo. We obtained PBMCs from healthy volunteers that had been genotyped for the TLR7 SNPs, stimulated the cells employing the TLR7-specific ligand Imiquimod and measured IFNa as well as IL-6 secretion in the supernatants. Donors hemizygous for the rare 'Leu'allele were compared with matched donors hemizygous for the common 'Gln' variant. Following Imiquimod treatment at 5 mmol/l, a timedependent IFNa responsewas observed which was lower in 'Leu' hemizygotes than in 'Gln' hemizygotes (P ¼ 0.05).
Regarding IL-6 response, the difference was weak and did not reach statistical significance (Fig. 3a) . Next, we assessed dose-response relationships following 8 and 24 h of Imiquimod treatment. Again, presence of the 'Leu' allele was associated with decreased IFNa levels, whereas IL-6 levels were similar in donors of both genotypes (Fig. 3b,c) . After normalization according to LPS-induced IL-6 levels, a TLR7-independent measure of cell activation, significance levels did not change (data not shown). These findings imply that TLR7 activation leads to a weakened IFNa response in TLR7 Gln11Leu SNP carriers as compared with wild type controls.
Of interest, the shapes of IFNa and IL-6 dose-response curves differed. Depending on TLR7 genotype and incubation time, maximum IFNa concentrations were induced by Imiquimod-doses between 5 and 10 mmol/l, whereas higher doses led to diminished IFNa levels; a cytopathic effect of the higher Imiquimod doses seems unlikely because for IL-6, at doses up to 100 mmol/l, a steadily increasing response was observed.
Discussion
TLRs are of crucial importance for the detection of viruses and the subsequent elicitation of an antiviral response [6] .
Clearance of a variety of viral infections, for example, vesicular stomatitis virus, cytomegalovirus and hepatitis B virus is critically dependent on TLR activation [64] [65] [66] .
TLR7/8 stimulation has been demonstrated to confer anti-HIV activity in vivo [13, 14] and ex vivo [15, 16] . On the other hand, TLR7/8 triggering has recently been implicated with persistent immune activation, a hallmark of progressive HIV-1 infection [32] [33] [34] . It therefore has been suggested by others that modulation of TLR7/8 signaling may represent a novel concept for future antiviral therapy [32] [33] [34] . We have recently identified a functional TLR8 variant associated with a restriction of HIV-1 disease [50] and in the present study present evidence for the association of a functional TLR7 variant with HIV-1 disease progression.
We detected a robust relationship between the TLR7 'Leu' genetic variant and higher set point viral loads. Progression to an advanced stage of immune suppression was accelerated in TLR7 'Leu' carriers. We observed that presence of the TLR7Gln11Leu SNP was associated with lower baseline CD4 þ T-cell counts and possibly increased HIV-1 susceptibility in women; these results are suggestive of a strong effect on the initial stages of HIV infection. Assuming that the deleterious effect of the TLR7 Gln11Leu genetic alteration depends on a diminished IFNa induction, these findings would be in line with the fact that IFNa production is of importance for the control of HIV replication during early, rather than late disease stages [24] [25] [26] .
We observed an overrepresentation of the rare TLR7-Gln11Leu genetic variant in HIV-1 infected females as compared with HIV-negative controls implying an increased risk for HIV-1 acquisition. This association was found in female but not male study participants; possible explanations may involve the significant genderspecific variation of IFNa levels induced by TLR7 ligands [67] . The number of women included in our study is less and the observed effect may well be due to a stochastic event only. Thus, confirmatory studies involving higher numbers of female participants are needed; however, in a cohort of female patients with chronic HCV infection, a significantly increased frequency of this SNP was also reported [68] . Taken together with these findings, our results suggest that, in vivo, presence of the TLR7 'Leu' variant is associated with a genderdependent increase of susceptibility not only to one but to various RNA viral diseases.
In our stimulation assays, the presence of the TLR7Gln11Leu variant was associated with decreased IFNa production. The induction of IL-6 was only marginally impaired. Although these data do not allow for direct conclusions on how this SNP exacerbates the course of HIV-1 disease, they suggest a selective impairment of the IRF7-dependent signaling pathway in TLR7Gln11Leu variant carriers. As a consequence, these individuals might suffer from a restriction of the antiretroviral IFNa response, leading to higher viral loads and accelerated disease progression. Moreover, the NFkB-dependent pathway culminating in the secretion of proinflammatory cytokines appears to remain unaltered. Thus, the mutant TLR7 protein would still be able to recognize HIV-1 RNA and contribute to chronic activation of the immune system, which is of major importance in AIDS pathogenesis [27, 33] . pDCs are of paramount importance in linking innate and adaptive immunity to HIV and many other viruses. They are also the PBMC sub-population responsible for the bulk of IFNa production following TLR7 stimulation [37] . Further studies are needed and currently underway in our laboratory to examine the effect of the Gln11Leu SNP on the IFNa and inflammatory cytokine response in pDCs.
At this point, we can only speculate about the molecular mechanism underlying the effect of the TLR7 Gln11Leu SNP on cytokine and interferon responses; possible explanations for its relevance include linkage disequilibrium with another genetic variation accounting for functional implications. However, this SNP is located in the signal sequence of TLR7, adjacent to the typical basic residues in the N-terminal part of this sequence. Signal peptide degeneracy, even when subtle, is known to modulate posttranslational modification, localization, quantity and thus the functionality of the affected protein [69] . The IRF-7 dependent pathway is characterized by a higher signaling threshold than the NF-kB dependent pathway [39] . Thus, lower quantities or impaired functionality of the variant TLR7 protein would indeed disturb IFNa rather than interleukin production.
The substantial impact of the host's genetic variation on the individual course of HIV-1 infection has been established during the last years and is subject of ongoing major studies [43, 47, 70, 71] . The important role of TLRs, in particular TLR7, in HIV pathogenesis is currently being elucidated [11, 12, 15, 16, 34] . The data presented here demonstrates for the first time that TLR7 genetic variability influences HIV-1 progression. The whole genome association studies [71] that are currently underway will be needed to assess the relative contribution of genetic variation of this and other TLRs to the total genetic impact.
In summary, our results demonstrate the effect of a TLR7 genetic polymorphism on HIV disease progression in a German seroconverter cohort. Furthermore, presence of this polymorphism might lead to a gender-specific increase of the risk to acquire HIV-1. In TLR7-specific stimulation assays, we show ex vivo that presence of this mutation is associated with decreased production of IFNa but normal production of IL-6. This combination of limited antiretroviral IFNa activity with an unaltered degree of immune activation is a potential underlying mechanism for the exacerbated disease course in SNP carriers. The data presented here may help define an individual patient's HIV-1 risk profile. They are of interest with regard to the potential of TLR7 agonists and antagonists as immunomodulatory antiretroviral drugs.
